Johnson & Johnson vaccine 66 percent effective, drops against South Africa variant | The Hill: Healthcare Policy

A COVID-19 single-shot vaccine from Johnson & Johnson was 66 percent effective in preventing moderate or severe disease in a Phase 3 clinical trial, a level of protection above the Food and Drug Administration's minimum, but lower than approved...